2Milsom I, Abrams P, Cardozo L, et al. How wide spread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Bju Int, 2001,87 ( 9 ) : 760- 766.
3schwinn DA,Miehelotti GA. Alphal-adrenergie receptors in the lower urinary tract and vascular bed:potential role for the alphald subtype in filling symptoms and effects of ageing on vascular expression. BJN Int,2000,85 Suppl 2:6-11.
4Lepor H. Phase Ill muhicenter placebo-controlled study of tamsulo- sin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology, 1998,51 (6) :892-900.
3Milsom I, Stewart W, Thuroff J. The prevalence of overactive blad- der. Am J Manag Care ,2006,11 (Suppl) : s565-s573.
4Killeher C J, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifena- cin. BJU Int,2005,95 (1) :81-85.
5Chapple CR. Darifenacin:a novel M3 muscarinic selective recep- tor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs ,2006,13 ( 11 ) : 1493-1500.
